Treatment of Patients With Castration Resistant Prostate Cancer Using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccine
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs ETBX- 071 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 18 Nov 2019 Status changed from active, no longer recruiting to suspended.
- 03 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated